

101018963

C of e

PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No. : 7,078,403
Issue Date : July 18, 2006
Inventors : Wen-Yang Wu et al.
Docket No. : 150070.401USPC
Date : August 22, 2007

Mail Stop Certificate of Correction
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

*Certificate
AUG 27 2007
of Correction*

REQUEST FOR CERTIFICATE OF CORRECTION

Commissioner for Patents:

A certificate of correction is respectfully requested in the above-identified patent. The following errors have been made:

In Claim 1, column 42, line 67, the phrase "hydrogen, di(C₁₋₆alkylamino, cyano, formyl," is incorrect. The correct phrase is "hydrogen, C₁₋₆alkyl, halo, hydroxyl, mercapto, haloC₁₋₄alkyl, amino, mono(C₁₋₆alkylamino), di(C₁₋₆alkyl)amino, cyano, formyl.". This error incurred through the fault of the Patent Office, as evidenced by Applicants' Listing of Claims in the Amendment filed on November 29, 2004.

In Claim 1, column 43, line 14, the phrase "O, SO or SO₂" is incorrect. The correct phrase is "O, S, SO or SO₂". This error incurred through the fault of the Patent Office, as evidenced by Applicants' Listing of Claims in the Amendment filed on November 29, 2004.


In Claim 1, column 44, line 47, the term "-CH₂)₂" is incorrect. The correct term is "-(CH₂)₂". This error incurred through the fault of the Patent Office, as evidenced by Applicants' Listing of Claims in the Amendment filed on November 29, 2004.

In Claim 1, column 44, line 48, the term "-CH₂)₂O-" is incorrect. The correct term is "-CH₂O-". This error incurred through the fault of the Patent Office, as evidenced by Applicants' Listing of Claims in the Amendment filed on November 29, 2004.


In Claim 15, column 45, lines 17-25, the formula:

AUG 27 2007

Request for Certificate of Correction
Patent No. 7,078,403



is incorrect. The correct formula is:




This error incurred through the fault of the Patent Office, as evidenced by Applicants' Listing of Claims in the Amendment filed on November 29, 2004. It is noted that issued claim 15 was claim 17 during prosecution.


In Claim 15, column 45, line 35, the term "C₁₋₆-alkyl" is incorrect. The correct term is "C₁₋₆alkyl". This error incurred through the fault of the Patent Office, as evidenced by Applicants' Listing of Claims in the Amendment filed on November 29, 2004. It is noted that issued claim 15 was claim 17 during prosecution.

In Claim 15, column 45, line 36, the term "cashe" is incorrect. The correct term is "each". This error incurred through the fault of the Patent Office, as evidenced by Applicants' Listing of Claims in the Amendment filed on November 29, 2004. It is noted that issued claim 15 was claim 17 during prosecution.

In Claim 16, column 45, lines 47-55, the formula:



is incorrect. The correct formula is:



AUG 27 2007

Request for Certificate of Correction
Patent No. 7,078,403

This error incurred through the fault of the Patent Office, as evidenced by Applicants' Listing of Claims in the Amendment filed on November 29, 2004. It is noted that issued claim 16 was claim 18 during prosecution.

In Claim 25, column 47, line 58, the term "Claim 24" is incorrect. The correct term is "Claim 23". This error incurred through the fault of the Patent Office, as evidenced by Applicants' Listing of Claims in the Amendment filed on November 29, 2004. It is noted that issued claim 25 was claim 29 during prosecution.

In Claim 27, column 48, lines 62-63, the compound name "1-(4-{2-[1-Chloro-pyridazin-3-yl]-piperidin-4-yl}-ethoxy)-phenyl)-propan-1-one O-allyl-oxime" is incorrect. The correct name is 1-(4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-phenyl)-propan-1-one O-allyl-oxime". This error incurred through the fault of the Patent Office, as evidenced by Applicants' Listing of Claims in the Amendment filed on November 29, 2004. It is noted that issued claim 27 was claim 32 during prosecution.

In Claim 27, column 49, lines 16-7, the compound name "3-Methyl-4-{2-[1-(methyl-pyridazin-3-yl)-piperidin-4-yl-ethoxy]-benzaldehyde O-methyl oxime" is incorrect. The correct name is "3-Methyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl-ethoxy]-benzaldehyde O-methyl oxime". This error incurred through the fault of the Patent Office, as evidenced by Applicants' Listing of Claims in the Amendment filed on November 29, 2004. It is noted that issued claim 27 was claim 32 during prosecution.

In Claim 28, column 50, lines 62-63, the compound name "3-[1-(Chloro-pyridazin-3-yl)-piperidin-4-ylmethoxy]-benzaldehyde O-allyl-oxime" is incorrect. The correct name is "3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-ylmethoxy]-benzaldehyde O-allyl-oxime". This error incurred through the fault of the Patent Office, as evidenced by Applicants' Listing of Claims in the Amendment filed on November 29, 2004. It is noted that issued claim 28 was claim 33 during prosecution.

In Claim 28, column 51, lines 18-19, the compound name "4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-indan-1-one O-ethyl-oxime" is incorrect. The correct name is "4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-indan-1-one O-ethyl-oxime". This error incurred through the fault of the Patent Office, as evidenced by Applicants' Listing of Claims in the Amendment filed on November 29, 2004. It is noted that issued claim 28 was claim 33 during prosecution.

In Claim 29, column 52, lines 4-5, the compound name "3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde O-2-oxo-propyl)-oxime" is incorrect. The correct name is "3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde O-(2-oxo-propyl)-oxime". This error incurred through the fault of the Patent Office, as evidenced by Applicants' Listing of Claims in the Amendment filed on November 29, 2004. It is noted that issued claim 29 was claim 34 during prosecution.


In Claim 29, column 52, lines 16-17, the compound name "3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-3,5-dimethyl-benzaldehyde O-(2-fluoro-ethyl)-oxime" is incorrect. The correct name is "3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde O-(2-fluoro-ethyl)-oxime". This error

Request for Certificate of Correction
Patent No. 7,078,403

incurred through the fault of the Patent Office, as evidenced by Applicants' Listing of Claims in the Amendment filed on November 29, 2004. It is noted that issued claim 29 was claim 34 during prosecution.

The above errors are errors of consequence. Accordingly, issuance of a Certificate of Correction is respectfully requested. Attached is form PTO/SB/44, which indicates the corrections to be made, by reference to the column and line numbers in the printed patent. Because the errors were made on behalf of the Patent Office, no fee is necessary. However if the errors are determined to have been errors made on behalf of the Applicants, the Director is hereby authorized to charge payment of any fees associated with this communication to Deposit Account No. 19-1090.

Respectfully submitted,
SEED Intellectual Property Law Group PLLC



Carol J. Roth
Registration No. 32, 783

CJR:dj

Enclosures:

Certificate of Correction
Postcard

SEED Intellectual Property Law Group PLLC
701 Fifth Avenue, Suite 5400
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031
1009600_1.DOC

AUG 27 2007

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : 7,078,403
DATED : July 18, 2006
INVENTORS : Wen-Yang Wu et al.

It is certified that an error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 42

Line 67, the phrase "hydrogen, di(C₁₋₆alkylamino, cyano, formyl" should read as --hydrogen, C₁₋₆alkyl, halo, hydroxyl, mercapto, haloC₁₋₄alkyl, amino, mono (C₁₋₆alkylamino), di(C₁₋₆alkyl)amino, cyano, formyl--.

Column 43

Line 14, the phrase "is O, SO or SO₂" should read as --is O, S, SO or SO₂--.

Column 44

Line 47, the term "-CH₂)₂-" should read as ---(CH₂)₂---.


Column 44

Line 48, the term "-CH₂)₂O-" should read as ---CH₂O---.

Column 45


Lines 17-25, the formula

"



" should read as

--



--.

MAILING ADDRESS OF SENDER:

Carol J. Roth
Seed Intellectual Property Law Group PLLC
701 Fifth Avenue, Suite 5400
Seattle, Washington 98104

PATENT NO. 7,078,403

No. of additional copies

AUG 27 2007

Burden hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : 7,078,403
DATED : July 18, 2006
INVENTORS : Wen-Yang Wu et al.

It is certified that an error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:


Column 45

Line 35, the term "C₁₋₆-alkyl" should read as --C₁₋₆alkyl--.

Line 36, the term "cashe" should read as --each--.


Lines 47-55, the formula

"



" should read as

--



--.

Column 47

Line 58, the term "claim 24" should read as --claim 23--.

Column 48

Line 62-63, the compound name "1-(4-[2-[1-Chloro-pyridazin-3-yl]-piperidin-4-yl]-ethoxy)-phenyl)-propan-1-one O-allyl-oxime" should read as --1-(4-[2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy)-phenyl)-propan-1-one O-allyl-oxime--.

Column 49

Line 16-17, the compound name "3-Methyl-4-[2-[1-(methyl-pyridazin-3-yl)-piperidin-4-yl-ethoxy]-benzaldehyde O-methyl oxime" should read as --3-Methyl-4-[2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl-ethoxy]-benzaldehyde O-methyl oxime--.

MAILING ADDRESS OF SENDER:

Carol J. Roth
Seed Intellectual Property Law Group PLLC
701 Fifth Avenue, Suite 5400
Seattle, Washington 98104

PATENT NO. 7,078,403

No. of additional copies
AUG 27 2007

Burden hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : 7,078,403
DATED : July 18, 2006
INVENTORS : Wen-Yang Wu et al.

It is certified that an error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 50

Line 62-63, the compound name "3-[1-(Chloro-pyridazin-3-yl)-piperidin-4-ylmethoxy]-benzaldehyde O-allyl-oxime" should read as --3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-ylmethoxy]-benzaldehyde O-allyl-oxime--.

Column 51

Line 18-19, the compound name "4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4yl]-ethoxy}-indan-1-one O-ethyl-oxime" should read as --4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-indan-1-one O-ethyl-oxime--.

Column 52

Line 4-5, the compound name "3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde O-2-oxo-propyl)-oxime" should read as --3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde O-(2-oxo-propyl)-oxime--.

Lines 16-17, the compound name "3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-3,5-dimethyl-benzaldehyde O-(2-fluoro-ethyl)-oxime" should read as --3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde O-(2-fluoro-ethyl)-oxime--.

MAILING ADDRESS OF SENDER:

Carol J. Roth
Seed Intellectual Property Law Group PLLC
701 Fifth Avenue, Suite 5400
Seattle, Washington 98104

PATENT NO. 7,078,403

No. of additional copies

Burden hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

AUG 27 2007